International Non-Proprietary Name (INN): none
Dosage Form: lyophilisate for preparation of solution for intramuscular injections (3, 5 ml)
Structure:
Active substance: cortexin (complex of water-soluble polypeptide fractions): 5 mg in 3 ml vial and 10 mg in 5 ml vial.
Auxiliary substance: glycine (stabilizer).
Description:
Lyophilized powder or porous mass of white or white-yellowish colour.
Pharmacological classification: nootropics
ATC code: N06BX
Pharmacological action: neuroprotective, nootropic, antioxidant, tissue-specific
CORTEXIN®
PHARMACODYNAMICS
Cortexin improves brain metabolism. The drug is a lyophilisate obtained by acetic acid extraction from the cerebral cortex of cattle or pigs. It contains low-molecular active neuropeptides (molecular weight does not exceed 10,000 daltons) which penetrate easily the blood-brain barrier and directly affect nervous cells.
Cortexin has a tissue-specific multifunctional effect on the brain. It promotes metabolic regulation, neuroprotection, functional neuromodulation, neurotrophic activity.
Cortexin improves the energy metabolism of brain cells as well as intracellular protein synthesis.
Cortexin regulates the processes of lipid peroxidation in brain cells, reduces the formation of free radicals and blocks the processes of free radical oxidation. The drug eliminates the imbalance of inhibitory and excitatory amino acids and possesses a moderate GABAergic effect.
Cortexin has a positive effect in the violation of cognitive functions. It improves concentration of attention, short-term memory, learning ability, accelerates recovery of brain functions after stress and regulates serotonin and dopamine levels. Cortexin stimulates mental activity (no excessive activating influence) and reparative processes in the brain as well as restores the cerebral bioelectrical activity.
PHARMACOKINETICS
Complexity of the drug`s composition does not allow for the conducting of the usual pharmacokinetic analysis of individual components, since the Cortexin active substance consists of a complex of polypeptide fractions.
INTENDED USES
Cerebral circulation disorders, encephalopathy of various genesis, acute and chronic encephalitis and encephalomyelitis, vegetative-vascular dystonia; epilepsy, craniocerebral trauma and its consequences, asthenia, viral and bacterial neuroinfections, infantile cerebral palsy, psychomotor and speech retardation in children, cognitive disorders (dysfunction of memory and ideation), reduced learning capacity.
SIDE EFFECTS
No side effects are detected.
Possible individual hypersensitivity to the components of the drug.
Overdose: No cases of drug overdose have been reported.
Interaction with other drugs: No data.
SPECIAL INSTRUCTIONS
Consult with your doctor before use.
Do not store / use after storage the dissolved preparation. It is not recommended to mix Cortexin with other solutions.
In case you have missed an injection, it is not recommended to administer a double dose, just carry out the next injection as usual on the target day.
Pregnancy and lactation: The drug is contraindicated during pregnancy due to the lack of data from clinical studies. If it is necessary to prescribe the drug during lactation, breastfeeding should be discontinued.
Influence on the ability to drive vehicles and operate machines: Cortexin does not affect the ability to drive vehicles and operate machines.
Terms of release from pharmacy: on prescription.
Storage conditions: Store in a dry dark place at temperatures of 2° to 20° C. Keep in a safe place out of reach of children.
Shelf life: 3 years. Do not use beyond the expiration date printed on the package.
Country of manufacture: Russia